Study Design: Human Leukocyte Antigen Class I Molecule A^∗02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation.

ABSTRACT:

Introduction

Cell therapy with regulatory T cells (Tregs) in solid organ transplantation is a promising approach for the prevention of graft rejection and induction of immunologic tolerance. Previous clinical studies have demonstrated the safety of Tregs in renal transplant recipients. Antigen-specific Tregs, such as chimeric antigen receptor (CAR)-Tregs, are expected to be more efficacious than polyclonal Tregs in homing to the target antigen. We have developed an autologous cell therapy (TX200-TR101) where a human leukocyte antigen (HLA) class I molecule A^∗02 (HLA-A^∗02)-CAR is introduced into autologous naive Tregs from a patient with HLA-A^∗02-negative end-stage renal disease (ESRD) awaiting an HLA-A^∗02-positive donor kidney.

Methods

SUBMITTER: Schreeb K 

PROVIDER: S-EPMC9174048 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature